Hospital Fluid Culture and Outcomes in Patients With Sepsis, Septic Shock
To what extent does hospital fluid culture influence the mortality rates of patients with severe sepsis and septic shock?
CHEST 2021
Conference Coverage
Noninvasive and Invasive Ventilation for Asthma Exacerbations in Children
To address the void in data on ventilation trends among children with asthma, investigators analyzed data from the largest US all-payer database.
NAVIGATOR Trial Outcomes for Tezepelumab Use in Severe, Uncontrolled Asthma
An analysis of NAVIGATOR trial data on tezepelumab use assessed patient-reported outcomes related to asthma control, symptoms, and HRQoL.
A New Basis for Predicting Future COPD Exacerbations During the Pandemic
Research presented at CHEST 2021 assessed an alternative approach to predicting COPD exacerbations during the COVID-19 pandemic.
Patients With Asthma Who Use Cannabis: Characteristics and Outcomes
With cannabis use on the rise, what do we know about patients with asthma who use cannabis?
Raised D-Dimer Linked to Mortality in Black Individuals With COVID-19 Pneumonia
A NYC hospital study explored disease severity in Black individuals with COVID-19 pneumonia, using D-dimer as a surrogate marker.
An Efficient, Minimally Invasive Pathway to Manage Suspicious Lung Nodules
Research presented at CHEST 2021 examines use of a single anesthesia episode for robotic navigational bronchoscopy and pulmonary resection for lung nodules.
E-Cigarette Use Associated With Increased Odds of Asthma and COPD
Researchers evaluated the relationship between e-cigarettes and obstructive pulmonary diseases, taking into account age, gender, ethnicity, and body mass index.
Efficacy and Safety of Gefapixant for Refractory/Unexplained Chronic Cough
Researchers conducted pooled analysis of the COUGH-1 and COUGH-2 phase 3 trials of gefapixant for treating refractory/unexplained chronic cough.
Tezepelumab Improves Lung Function in Severe, Uncontrolled Asthma
NAVIGATOR trial results presented at CHEST 2021 show the effect of tezepelumab on peak expiratory flow rates in severe asthma.
Want to read more?
Please login or register first to view this content.